Palo Alto Investors LP Makes New $391.32 Million Investment in Inspire Medical Systems, Inc. $INSP

Palo Alto Investors LP acquired a new stake in Inspire Medical Systems, Inc. (NYSE:INSP) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 8,772 shares of the company’s stock, valued at approximately $391,319,000.

A number of other institutional investors have also recently made changes to their positions in the stock. CWM LLC increased its stake in shares of Inspire Medical Systems by 216.1% in the fourth quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after buying an additional 242 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Inspire Medical Systems by 1,115.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock valued at $33,000 after buying an additional 580 shares during the last quarter. Havemeyer Place LP purchased a new stake in Inspire Medical Systems during the 4th quarter valued at $39,000. Smartleaf Asset Management LLC boosted its position in Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after buying an additional 205 shares during the period. Finally, Versant Capital Management Inc grew its holdings in Inspire Medical Systems by 379.0% in the 2nd quarter. Versant Capital Management Inc now owns 958 shares of the company’s stock worth $43,000 after acquiring an additional 758 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Trading Down 1.6%

Shares of INSP opened at $60.84 on Friday. Inspire Medical Systems, Inc. has a 1-year low of $38.91 and a 1-year high of $147.03. The firm’s 50-day moving average price is $52.73 and its 200-day moving average price is $52.44. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of 13.17, a PEG ratio of 4.70 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. During the same period in the prior year, the firm earned $0.45 earnings per share. Inspire Medical Systems’s revenue was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, research analysts forecast that Inspire Medical Systems, Inc. will post 1.24 EPS for the current fiscal year.

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, insider Jason P. Kelly sold 963 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total transaction of $57,346.65. Following the transaction, the insider owned 18,985 shares in the company, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on INSP shares. KeyCorp reaffirmed a “sector weight” rating on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Robert W. Baird raised their target price on Inspire Medical Systems from $54.00 to $59.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Oppenheimer upgraded Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price target on the stock in a report on Tuesday, August 4th. Evercore set a $54.00 price target on Inspire Medical Systems in a research report on Tuesday, August 4th. Finally, Bank of America lowered Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price target for the company. in a research report on Friday, May 22nd. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Inspire Medical Systems currently has an average rating of “Hold” and a consensus price target of $66.19.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.